Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares of Initial Public Offering
Get Alerts VTAE Hot Sheet
Join SI Premium – FREE
FORT WASHINGTON, Pa., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE), a clinical stage biotechnology company, today announced that the underwriters of its previously announced initial public offering (IPO) of common stock have exercised in full their option to purchase 1,031,250 shares of common stock at the IPO price of $8.00 per share, less underwriting discounts. After giving effect to the over-allotment closing, the aggregate net proceeds to Vitae from the IPO, after underwriting discounts and commissions and estimated offering expenses, was approximately $56.0 million.
Stifel and BMO Capital Markets acted as joint book-running managers and JMP Securities and Wedbush PacGrow Life Sciences acted as co-managers for the IPO.
A copy of the final prospectus related to the IPO may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, Telephone: (415) 364-2720, email: [email protected]; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, 27th Floor, New York, NY 10036, Telephone: (800) 414-3627, email: [email protected].
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
CONTACT: Investors: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 [email protected] Westwicke Partners John Woolford (443) 213-0506 [email protected] or Media: 6 Degrees PR Tony Plohoros (908) 940-0135 [email protected]Source: Vitae Pharmaceuticals
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Keurig Dr Pepper Inc. (KDP) Confirms Previously Announced Resignation of CEO Gamgort, Appoints Timothy Cofer New CEO
- USCB Financial Holdings (USCB) Reports Q1, Announces 500K Share Buyback
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
BMO Capital, JMP Securities, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!